ivWatch Strengthens Leadership Team with Board Appointments, New President and VP of Sales to Drive Growth

IV safety company adds prominent healthcare leaders to board, expands executive roster to further accelerate the commercialization of breakthrough IV monitoring technology

NEWPORT NEWS, Va., Sept. 18, 2025 /PRNewswire/ -- ivWatch, LLC, the IV safety company, today announced it has appointed Jack Diamond, Paul Kempinski, MS, FACHE, CEC, and John Palumbo to the company's board of managers, collectively bringing decades of healthcare leadership and business growth expertise to its leadership team. The company also appointed chief marketing and communications officer Erin Wendell as president and named medical device veteran Wayne Shepherd as vice president of U.S. sales to lead its next phase of commercialization.

IV infiltration and extravasation adverse events represent some of the most frequent and costly complications in hospital care, with failure rates in infusion therapy nearing 50 percent, and higher for vulnerable patient populations. ivWatch's continuous monitoring system is the first and only FDA-cleared and CE-marked technological solution designed specifically to address this issue, enabling hospitals to improve patient safety while alleviating clinical, legal, and financial pressures.

"We're excited to welcome our accomplished new board members who offer invaluable insider knowledge of healthcare systems and growth strategy, while Erin and Wayne bring track records of building high-performing commercialization strategies and sales teams that deliver results," said John Lawson, Chairman of the Board of Managers. "The diversity of this team and their global experience, combined with their insights, position ivWatch to advance our go-to-market capabilities and accelerate growth."

Board Appointments

Jack Diamond
Co-Founder and CEO at Brennan, Manna & Diamond and co-founder of the American Bar Association's Health Law Section, Diamond has led hundreds of healthcare projects worldwide, including hospital campuses, clinical centers of excellence, and surgery centers. Recognized among America's top health law attorneys, he is an expert at guiding organizations through complex healthcare regulations.

Paul Kempinski, MS, FACHE, CEC
Former president and CEO of Children's Mercy Kansas City, Kempinski has over four decades of leadership experience in pediatric and adult hospital systems nationwide. Kempinski has led significant advancements in quality, safety, market growth, clinical program development, and financial strength. He served on the board of the Children's Hospital Association and chaired the association's quality committee. He is now President of Kempinski Consulting, LLC which provides executive coaching and advisory/governance support.

John Palumbo
Palumbo's healthcare career spans over 40 years covering a range of market segments. He has launched and grown early-stage companies and has led significant successful transformations in large Fortune 100 companies. For the past 15 years, he has focused on advisory and board work for sponsor-backed healthcare AI technology, tech-enabled services and device companies committed to clinical and technological innovation. He specializes in guiding leadership to create and sustain a high-performance culture, execute successful go-to-market strategies, and create shareholder wealth.

A growth-focused healthcare executive, Palumbo has held senior leadership roles at Allscripts, Premise Health, Cencora, and Siemens. He has guided companies through IPOs, growth investments and control processes. He has served on multiple healthcare boards, including Aligne Health, ValueHealth, PM Pediatrics and QLess.

New President – Erin Wendell
ivWatch's chief marketing and communications officer, Erin Wendell, has been elevated to president, bringing expertise from multiple industries and the ability to navigate the complex medical market. Since joining ivWatch in 2020, she has spearheaded initiatives that advanced the company's commercial presence and reach, rebranded ivWatch, driven several international market launches, and developed the company's holistic go-to-market strategies.

By fostering close collaboration between sales, clinical, and marketing, Wendell has helped align strategy with execution, ensuring consistent messaging and measurable results that will accelerate commercialization. Her leadership raised ivWatch's profile and market awareness, resulting in ivWatch receiving Inc. Magazine's Best in Business award and being named to Fast Company's Most Innovative Companies list last year.

New Vice President of Sales – Wayne Shepherd
Wayne Shepherd brings more than 30 years of sales leadership in the medical device, equipment, and diagnostics sectors. He has created and developed new markets while building and leading high-performing commercial teams across multiple disease states within the life sciences, hospital, and outpatient segments. At AccuVein, he oversaw the expansion of the sales team from six to 64, while increasing revenue from $2M to $30M, and most recently at Grenova, he drove significant global growth through new customer acquisition and market development.

By adding Shepherd to the leadership team, ivWatch is strengthening its commercialization strategy and positioning the company to scale adoption of its patented sensor technology across hospitals and health systems in the U.S.

For more information on how the ivWatch technology works, visit: https://www.ivwatch.com/tech-overview/.

About ivWatch
IV insertion is the most common hospital procedure, yet up to 50% of them fail, often with severe consequences ranging from dosing errors, scarring, skin staining, nerve damage, amputation, and even death. Newport News, Virginia-based ivWatch is changing that. 

Founded in 2010 and holding nearly 70 patents and counting, the company has developed a first-of-its-kind Class II medical device, cleared by the FDA and CE-marked, that uses visible and near-infrared light and a predictive algorithm to continuously monitor peripheral IVs to aid in the early detection of IV leakage events, also known as infiltration and extravasation.

Applied to the skin at the IV site, ivWatch sensors perform over 18,000 checks per hour for signs of IV infiltration and extravasation, notifying healthcare workers of fluid leakage outside of the vein in real time to reduce severe adverse outcomes.

In 2024, the company surpassed more than 35 clinical bodies of evidence. It was also named to Fast Company's Most Innovative Companies list, the Inc. 2024 Best in Business list in the Health Products category, and was recognized by Modern Healthcare as one of its 2024 Best in Business. The company also reached the Top 3 in the 2024 Startup World Cup Grand Finale, from an initial group of over 8,000 global startups. To learn more, visit www.ivwatch.com.

SOURCE ivWatch, LLC